# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology compan...
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology compan...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimat...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
Financial Results: Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, ...
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.